Zenas BioPharma, Inc. Common Stock (ZBIO)

• Market cap: $468M
• 1 day: 12.56%
• 5 days: 14.40%
• 1 month: 41.77%
• 3 months: 53.64%
• 6 months: -45.60%
• Year to date: 24.31%
• 1 year: -38.29%
• 5 years: -38.29%
• 10 years: -38.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.

Employees: 130

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 14

117% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 6

49% more funds holding

Funds holding: 43 [Q3] → 64 (+21) [Q4]

13.78% more ownership

Funds ownership: 62.07% [Q3] → 75.85% (+13.78%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

38% less capital invested

Capital invested by funds: $417M [Q3] → $260M (-$158M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $19 70% upside
• Avg. target: $32 188% upside
• High target: $45 302% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Wedbush Martin Fan 50% 1-year accuracy 1 / 2 met price target	213% upside $35	Outperform Initiated	20 Mar 2025
Guggenheim Yatin Suneja 27% 1-year accuracy 9 / 33 met price target	302% upside $45	Buy Reiterated	12 Mar 2025
HC Wainwright & Co. Matthew Caufield 25% 1-year accuracy 17 / 67 met price target	168% upside $30	Buy Reiterated	12 Mar 2025
Wolfe Research Andy Chen 53% 1-year accuracy 8 / 15 met price target	70% upside $19	Outperform Initiated	4 Feb 2025